Coya Therapeutics (COYA) Competitors

Coya Therapeutics (NASDAQ:COYA) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk, media sentiment and community ranking.

Which has better earnings & valuation, COYA or FULC?

Coya Therapeutics has higher earnings, but lower revenue than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Coya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$3.69M	25.64	-$7.99M	-$1.07	-5.28
Fulcrum Therapeutics	$80M	4.58	-$97.33M	-$0.07	-97.00

Do insiders and institutionals hold more shares of COYA or FULC?

39.8% of Coya Therapeutics shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 12.0% of Coya Therapeutics shares are held by company insiders. Comparatively, 7.0% of Fulcrum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Is COYA or FULC more profitable?

Fulcrum Therapeutics' return on equity of -7.31% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	N/A	-31.63%	-27.76%
Fulcrum Therapeutics	N/A	-7.31%	-6.74%

Do analysts prefer COYA or FULC?

Coya Therapeutics currently has a consensus target price of $17.00, suggesting a potential upside of 200.88%. Fulcrum Therapeutics has a consensus target price of $6.29, suggesting a potential downside of 7.43%. Given Coya Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Coya Therapeutics is more favorable than Fulcrum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Fulcrum Therapeutics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

Does the MarketBeat Community believe in COYA or FULC?

Fulcrum Therapeutics received 75 more outperform votes than Coya Therapeutics when rated by MarketBeat users. However, 93.10% of users gave Coya Therapeutics an outperform vote while only 61.82% of users gave Fulcrum Therapeutics an outperform vote.

Company	Underperform	Outperform
Coya Therapeutics	Outperform Votes 27 93.10%	Underperform Votes 2 6.90%
Fulcrum Therapeutics	Outperform Votes 102 61.82%	Underperform Votes 63 38.18%

Which has more risk and volatility, COYA or FULC?

Coya Therapeutics has a beta of 0.22, meaning that its stock price is 78% less volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.41, meaning that its stock price is 141% more volatile than the S&P 500.

Does the media prefer COYA or FULC?

In the previous week, Fulcrum Therapeutics had 4 more articles in the media than Coya Therapeutics. MarketBeat recorded 9 mentions for Fulcrum Therapeutics and 5 mentions for Coya Therapeutics. Fulcrum Therapeutics' average media sentiment score of 1.09 beat Coya Therapeutics' score of 0.62 indicating that Fulcrum Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fulcrum Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Fulcrum Therapeutics beats Coya Therapeutics on 10 of the 18 factors compared between the two stocks.